Read More

NAYA Biosciences And ONK Therapeutics Announce Research Partnership To Advance Combination Therapy Of FLEX-NK Bispecific Antibodies And Optimally Engineered Off-The-Shelf Natural Killer Cell Therapies

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer

INVO

Read More

Cyprium Therapeutics, A Fortress Biotech Subsidiary Company, Completes Asset Transfer Of CUTX-101 Copper Histidinate Product Candidate For Treatment Of Menkes Disease, To Sentynl Therapeutics, A Wholly-Owned Subsidiary Of Zydus Lifesciences Ltd.

Cyprium received $4.5 million payment upon closing and remains eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium will retain 100% ownership over any FDA

FBIO